Cepheid Inks Hospital Distribution Deal, Launches SA/MRSA Test in Europe
Healthcare supply company Broadlane will sell Cepheid’s molecular diagnostics instruments, reagents, and services to its customers, which include more than 20,000 healthcare facilities in the US, Cepheid said last week.
Broadlane’s client base includes acute care hospitals, ambulatory care facilities, and physician’s offices, Cepheid said.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

An opinion piece in the Guardian argues that President Donald Trump is uninterested in science and that might not be a bad thing for the field.

The San Francisco Chronicle reports the Veterans Affairs Health System is studying whether genetic testing can help prescribe better depression therapies.

Stat News reports that Spark Therapeutics' Luxturna is now being used to treat a wider array of patients.

In Genome Biology this week: transcription factor use among brittle stars, single-cell RNA sequencing strategy, and more.